# Asymmetric Dimethylarginine: A Never-Aging Story

## TL;DR

This paper explores how asymmetric dimethylarginine (ADMA) may contribute to aging-related diseases and how removing it could promote healthier aging.

## Contribution

The paper highlights ADMA as a novel therapeutic target for delaying aging and reducing age-related diseases.

## Key findings

- ADMA is an independent risk factor for age-associated diseases.
- Selective removal of ADMA is a promising strategy to reduce disease burden in aging.
- ADMA inhibition of nitric oxide synthase is linked to aging and disease progression.

## Abstract

Human aging is intrinsically associated with the onset and the progression of
several disease states causing significant disability and poor quality of life.
Although such association was traditionally considered immutable, recent
advances have led to a better understanding of several critical biochemical
pathways involved in the aging process. This, in turn, has stimulated a
significant body of research to investigate whether reprogramming these pathways
could delay the progression of human ageing and/or prevent relevant disease
states, ultimately favoring healthier aging process. Cellular senescence is
regarded as the principal causative factor implicated in biological and
pathophysiological processes involved in aging. Asymmetric dimethylarginine
(ADMA) is an endogenous inhibitor of nitric oxide synthase and an independent
risk factor for several age-associated diseases. The selective extracorporeal
removal of ADMA is emerging as a promising strategy to reduce the burden of
age-associated disease states. This article discusses the current knowledge
regarding the critical pathways involved in human aging and associated diseases
and the possible role of ADMA as a target for therapies leading to healthier
aging processes.